A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14.

Authors

L Véronèse, A Tchirkov, C Richard-Pebrel, A Ledoux-Pilon, J Fleury, C Chaleteix, C Goumy, L Gouas, M G Berger, P Vago, J O Bay, O Tournilhac

PMID: 19833389
DOI: 10.1016/j.leukres.2009.09.025

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Amino Acid Substitution / physiology
Antineoplastic Agents / therapeutic use
Benzamides
Drug Resistance, Neoplasm / genetics
Drug Resistance, Neoplasm / physiology*
Female
Humans
Imatinib Mesylate
Janus Kinase 2 / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Male
Middle Aged
Myeloproliferative Disorders / complications
Myeloproliferative Disorders / diagnosis*
Myeloproliferative Disorders / genetics
Phenylalanine / genetics
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Thrombocytosis / chemically induced*
Thrombocytosis / genetics
Valine / genetics

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Phenylalanine
Imatinib Mesylate
JAK2 protein, human
Janus Kinase 2
Valine